ID   UBR1_YEAST              Reviewed;        1950 AA.
AC   P19812; D6VUW7;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   22-JUL-2015, entry version 144.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR1;
DE            EC=6.3.2.-;
DE   AltName: Full=N-end-recognizing protein;
DE   AltName: Full=N-recognin-1;
GN   Name=UBR1; Synonyms=PTR1; OrderedLocusNames=YGR184C; ORFNames=G7168;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina;
OC   Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=S288c / GRF88;
RX   PubMed=2209542;
RA   Bartel B., Wuenning I., Varshavsky A.;
RT   "The recognition component of the N-end rule pathway.";
RL   EMBO J. 9:3179-3189(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9133739;
RX   DOI=10.1002/(SICI)1097-0061(19970330)13:4<357::AID-YEA77>3.0.CO;2-J;
RA   Arroyo J., Garcia-Gonzalez M., Garcia-Saez M.I., Sanchez-Perez M.,
RA   Nombela C.;
RT   "DNA sequence analysis of a 23,002 bp DNA fragment of the right arm of
RT   Saccharomyces cerevisiae chromosome VII.";
RL   Yeast 13:357-363(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9169869;
RA   Tettelin H., Agostoni-Carbone M.L., Albermann K., Albers M.,
RA   Arroyo J., Backes U., Barreiros T., Bertani I., Bjourson A.J.,
RA   Brueckner M., Bruschi C.V., Carignani G., Castagnoli L., Cerdan E.,
RA   Clemente M.L., Coblenz A., Coglievina M., Coissac E., Defoor E.,
RA   Del Bino S., Delius H., Delneri D., de Wergifosse P., Dujon B.,
RA   Durand P., Entian K.-D., Eraso P., Escribano V., Fabiani L.,
RA   Fartmann B., Feroli F., Feuermann M., Frontali L., Garcia-Gonzalez M.,
RA   Garcia-Saez M.I., Goffeau A., Guerreiro P., Hani J., Hansen M.,
RA   Hebling U., Hernandez K., Heumann K., Hilger F., Hofmann B.,
RA   Indge K.J., James C.M., Klima R., Koetter P., Kramer B., Kramer W.,
RA   Lauquin G., Leuther H., Louis E.J., Maillier E., Marconi A.,
RA   Martegani E., Mazon M.J., Mazzoni C., McReynolds A.D.K.,
RA   Melchioretto P., Mewes H.-W., Minenkova O., Mueller-Auer S.,
RA   Nawrocki A., Netter P., Neu R., Nombela C., Oliver S.G., Panzeri L.,
RA   Paoluzi S., Plevani P., Portetelle D., Portillo F., Potier S.,
RA   Purnelle B., Rieger M., Riles L., Rinaldi T., Robben J.,
RA   Rodrigues-Pousada C., Rodriguez-Belmonte E., Rodriguez-Torres A.M.,
RA   Rose M., Ruzzi M., Saliola M., Sanchez-Perez M., Schaefer B.,
RA   Schaefer M., Scharfe M., Schmidheini T., Schreer A., Skala J.,
RA   Souciet J.-L., Steensma H.Y., Talla E., Thierry A., Vandenbol M.,
RA   van der Aart Q.J.M., Van Dyck L., Vanoni M., Verhasselt P., Voet M.,
RA   Volckaert G., Wambutt R., Watson M.D., Weber N., Wedler E., Wedler H.,
RA   Wipfli P., Wolf K., Wright L.F., Zaccaria P., Zimmermann M.,
RA   Zollner A., Kleine K.;
RT   "The nucleotide sequence of Saccharomyces cerevisiae chromosome VII.";
RL   Nature 387:81-84(1997).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M.,
RA   Cherry J.M.;
RT   "The reference genome sequence of Saccharomyces cerevisiae: Then and
RT   now.";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [5]
RP   INTERACTION WITH UBC2, AND MUTAGENESIS OF LYS-1168; ARG-1169;
RP   LYS-1173; CYS-1220; CYS-1223; CYS-1295; HIS-1297 AND CYS-1320.
RX   PubMed=10581257; DOI=10.1093/emboj/18.23.6832;
RA   Xie Y., Varshavsky A.;
RT   "The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger
RT   of E3 is required for the synthesis of multiubiquitin chain.";
RL   EMBO J. 18:6832-6844(1999).
RN   [6]
RP   INTERACTION WITH RPN2; RPT1 AND RPT6.
RX   PubMed=10688918; DOI=10.1073/pnas.060025497;
RA   Xie Y., Varshavsky A.;
RT   "Physical association of ubiquitin ligases and the 26S proteasome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:2497-2502(2000).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296 AND SER-300, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   STRAIN=ADR376;
RX   PubMed=17330950; DOI=10.1021/pr060559j;
RA   Li X., Gerber S.A., Rudner A.D., Beausoleil S.A., Haas W., Villen J.,
RA   Elias J.E., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of alpha-factor-arrested
RT   Saccharomyces cerevisiae.";
RL   J. Proteome Res. 6:1190-1197(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18407956; DOI=10.1074/mcp.M700468-MCP200;
RA   Albuquerque C.P., Smolka M.B., Payne S.H., Bafna V., Eng J., Zhou H.;
RT   "A multidimensional chromatography technology for in-depth
RT   phosphoproteome analysis.";
RL   Mol. Cell. Proteomics 7:1389-1396(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-300 AND
RP   SER-1938, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19779198; DOI=10.1126/science.1172867;
RA   Holt L.J., Tuch B.B., Villen J., Johnson A.D., Gygi S.P., Morgan D.O.;
RT   "Global analysis of Cdk1 substrate phosphorylation sites provides
RT   insights into evolution.";
RL   Science 325:1682-1686(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
CC   -!- FUNCTION: Ubiquitin ligase protein which is a component of the N-
CC       end rule pathway. Recognizes and binds to proteins bearing
CC       specific N-terminal residues that are destabilizing according to
CC       the N-end rule, leading to their ubiquitination and subsequent
CC       degradation.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with UBC2. Interacts with RPN2, RPT1 and RPT6
CC       from the 26S proteasome. {ECO:0000269|PubMed:10581257,
CC       ECO:0000269|PubMed:10688918}.
CC   -!- INTERACTION:
CC       P06104:RAD6; NbExp=3; IntAct=EBI-19909, EBI-19722;
CC       P32565:RPN2; NbExp=2; IntAct=EBI-19909, EBI-15919;
CC       P33299:RPT1; NbExp=2; IntAct=EBI-19909, EBI-13910;
CC       Q01939:RPT6; NbExp=4; IntAct=EBI-19909, EBI-13914;
CC   -!- DOMAIN: The RING-H2 zinc finger is an atypical RING finger with a
CC       His ligand in place of the fourth Cys of the classical motif.
CC   -!- SIMILARITY: Belongs to the UBR1 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 UBR-type zinc finger. {ECO:0000255|PROSITE-
CC       ProRule:PRU00508}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X53747; CAA37779.1; -; Genomic_DNA.
DR   EMBL; X99074; CAA67528.1; -; Genomic_DNA.
DR   EMBL; Z72969; CAA97210.1; -; Genomic_DNA.
DR   EMBL; BK006941; DAA08278.1; -; Genomic_DNA.
DR   PIR; S12332; S12332.
DR   RefSeq; NP_011700.1; NM_001181313.1.
DR   PDB; 3NIH; X-ray; 2.10 A; A=115-194.
DR   PDB; 3NII; X-ray; 2.10 A; A=115-194.
DR   PDB; 3NIJ; X-ray; 2.10 A; A=115-194.
DR   PDB; 3NIK; X-ray; 1.85 A; A/B/D/F=115-194.
DR   PDB; 3NIL; X-ray; 1.75 A; A/B/D/F=115-194.
DR   PDB; 3NIM; X-ray; 2.00 A; A/B/D/F=115-194.
DR   PDB; 3NIN; X-ray; 2.10 A; A/B=115-194.
DR   PDB; 3NIS; X-ray; 1.68 A; A/B/D/F=115-194.
DR   PDB; 3NIT; X-ray; 2.60 A; A=107-194.
DR   PDBsum; 3NIH; -.
DR   PDBsum; 3NII; -.
DR   PDBsum; 3NIJ; -.
DR   PDBsum; 3NIK; -.
DR   PDBsum; 3NIL; -.
DR   PDBsum; 3NIM; -.
DR   PDBsum; 3NIN; -.
DR   PDBsum; 3NIS; -.
DR   PDBsum; 3NIT; -.
DR   ProteinModelPortal; P19812; -.
DR   SMR; P19812; 115-194, 1291-1326.
DR   BioGrid; 33436; 155.
DR   DIP; DIP-2517N; -.
DR   IntAct; P19812; 10.
DR   MINT; MINT-596541; -.
DR   MaxQB; P19812; -.
DR   PaxDb; P19812; -.
DR   PeptideAtlas; P19812; -.
DR   EnsemblFungi; YGR184C; YGR184C; YGR184C.
DR   GeneID; 853096; -.
DR   KEGG; sce:YGR184C; -.
DR   CYGD; YGR184c; -.
DR   EuPathDB; FungiDB:YGR184C; -.
DR   SGD; S000003416; UBR1.
DR   eggNOG; NOG310244; -.
DR   GeneTree; ENSGT00530000063055; -.
DR   HOGENOM; HOG000142344; -.
DR   InParanoid; P19812; -.
DR   KO; K10625; -.
DR   OMA; TIRMNEI; -.
DR   OrthoDB; EOG76X67D; -.
DR   BioCyc; YEAST:G3O-30874-MONOMER; -.
DR   BRENDA; 2.3.2.B9; 984.
DR   BRENDA; 6.3.2.19; 984.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; P19812; -.
DR   NextBio; 973087; -.
DR   PRO; PR:P19812; -.
DR   Proteomes; UP000002311; Chromosome VII.
DR   GO; GO:0005737; C:cytoplasm; IMP:SGD.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IMP:SGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071629; P:cytoplasm-associated proteasomal ubiquitin-dependent protein catabolic process; IMP:SGD.
DR   GO; GO:0030433; P:ER-associated ubiquitin-dependent protein catabolic process; IMP:SGD.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:SGD.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:SGD.
DR   GO; GO:0090089; P:regulation of dipeptide transport; IMP:SGD.
DR   GO; GO:1990116; P:ribosome-associated ubiquitin-dependent protein catabolic process; IMP:SGD.
DR   GO; GO:0071596; P:ubiquitin-dependent protein catabolic process via the N-end rule pathway; IMP:SGD.
DR   InterPro; IPR003769; ClpS_core.
DR   InterPro; IPR003126; Znf_N-recognin.
DR   InterPro; IPR013993; Znf_N-recognin_met.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF02617; ClpS; 1.
DR   Pfam; PF02207; zf-UBR; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Ligase; Metal-binding;
KW   Phosphoprotein; Reference proteome; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   1950       E3 ubiquitin-protein ligase UBR1.
FT                                /FTId=PRO_0000056135.
FT   ZN_FING     121    194       UBR-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00508}.
FT   ZN_FING    1220   1324       RING-type; atypical.
FT   REGION     1117   1219       Interaction with UBC2.
FT   MOD_RES     296    296       Phosphoserine.
FT                                {ECO:0000269|PubMed:17330950,
FT                                ECO:0000269|PubMed:18407956,
FT                                ECO:0000269|PubMed:19779198}.
FT   MOD_RES     300    300       Phosphoserine.
FT                                {ECO:0000269|PubMed:17330950,
FT                                ECO:0000269|PubMed:19779198}.
FT   MOD_RES    1938   1938       Phosphoserine.
FT                                {ECO:0000269|PubMed:19779198}.
FT   MUTAGEN    1168   1168       K->S: Impairs interaction with UBC2, but
FT                                does not affect degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1169   1169       R->L: Impairs interaction with UBC2, but
FT                                does not affect degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1173   1173       K->A: Impairs interaction with UBC2, but
FT                                does not affect degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1220   1220       C->S: No effect on interaction with UBC2,
FT                                but inhibits degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1223   1223       C->S: No effect on interaction with UBC2,
FT                                but inhibits degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1295   1295       C->S: No effect on interaction with UBC2,
FT                                but inhibits degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1297   1297       H->A: No effect on interaction with UBC2,
FT                                but inhibits degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   MUTAGEN    1320   1320       C->S: No effect on interaction with UBC2,
FT                                but inhibits degradation of N-end rule
FT                                substrates.
FT                                {ECO:0000269|PubMed:10581257}.
FT   STRAND      132    136       {ECO:0000244|PDB:3NIS}.
FT   TURN        137    139       {ECO:0000244|PDB:3NIS}.
FT   STRAND      140    142       {ECO:0000244|PDB:3NIS}.
FT   TURN        149    151       {ECO:0000244|PDB:3NIS}.
FT   HELIX       154    157       {ECO:0000244|PDB:3NIS}.
FT   STRAND      162    166       {ECO:0000244|PDB:3NIS}.
FT   STRAND      169    174       {ECO:0000244|PDB:3NIS}.
FT   HELIX       180    182       {ECO:0000244|PDB:3NIS}.
FT   STRAND      183    185       {ECO:0000244|PDB:3NIS}.
FT   HELIX       190    192       {ECO:0000244|PDB:3NIS}.
SQ   SEQUENCE   1950 AA;  224838 MW;  33E4CD3A031AF523 CRC64;
     MSVADDDLGS LQGHIRRTLR SIHNLPYFRY TRGPTERADM SRALKEFIYR YLYFVISNSG
     ENLPTLFNAH PKQKLSNPEL TVFPDSLEDA VDIDKITSQQ TIPFYKIDES RIGDVHKHTG
     RNCGRKFKIG EPLYRCHECG CDDTCVLCIH CFNPKDHVNH HVCTDICTEF TSGICDCGDE
     EAWNSPLHCK AEEQENDISE DPATNADIKE EDVWNDSVNI ALVELVLAEV FDYFIDVFNQ
     NIEPLPTIQK DITIKLREMT QQGKMYERAQ FLNDLKYEND YMFDGTTTAK TSPSNSPEAS
     PSLAKIDPEN YTVIIYNDEY HNYSQATTAL RQGVPDNVHI DLLTSRIDGE GRAMLKCSQD
     LSSVLGGFFA VQTNGLSATL TSWSEYLHQE TCKYIILWIT HCLNIPNSSF QTTFRNMMGK
     TLCSEYLNAT ECRDMTPVVE KYFSNKFDKN DPYRYIDLSI LADGNQIPLG HHKILPESST
     HSLSPLINDV ETPTSRTYSN TRLQHILYFD NRYWKRLRKD IQNVIIPTLA SSNLYKPIFC
     QQVVEIFNHI TRSVAYMDRE PQLTAIRECV VQLFTCPTNA KNIFENQSFL DIVWSIIDIF
     KEFCKVEGGV LIWQRVQKSN LTKSYSISFK QGLYTVETLL SKVHDPNIPL RPKEIISLLT
     LCKLFNGAWK IKRKEGEHVL HEDQNFISYL EYTTSIYSII QTAEKVSEKS KDSIDSKLFL
     NAIRIISSFL GNRSLTYKLI YDSHEVIKFS VSHERVAFMN PLQTMLSFLI EKVSLKDAYE
     ALEDCSDFLK ISDFSLRSVV LCSQIDVGFW VRNGMSVLHQ ASYYKNNPEL GSYSRDIHLN
     QLAILWERDD IPRIIYNILD RWELLDWFTG EVDYQHTVYE DKISFIIQQF IAFIYQILTE
     RQYFKTFSSL KDRRMDQIKN SIIYNLYMKP LSYSKLLRSV PDYLTEDTTE FDEALEEVSV
     FVEPKGLADN GVFKLKASLY AKVDPLKLLN LENEFESSAT IIKSHLAKDK DEIAKVVLIP
     QVSIKQLDKD ALNLGAFTRN TVFAKVVYKL LQVCLDMEDS TFLNELLHLV HGIFRDDELI
     NGKDSIPEAY LSKPICNLLL SIANAKSDVF SESIVRKADY LLEKMIMKKP NELFESLIAS
     FGNQYVNDYK DKKLRQGVNL QETEKERKRR LAKKHQARLL AKFNNQQTKF MKEHESEFDE
     QDNDVDMVGE KVYESEDFTC ALCQDSSSTD FFVIPAYHDH SPIFRPGNIF NPNEFMPMWD
     GFYNDDEKQA YIDDDVLEAL KENGSCGSRK VFVSCNHHIH HNCFKRYVQK KRFSSNAFIC
     PLCQTFSNCT LPLCQTSKAN TGLSLDMFLE SELSLDTLSR LFKPFTEENY RTINSIFSLM
     ISQCQGFDKA VRKRANFSHK DVSLILSVHW ANTISMLEIA SRLEKPYSIS FFRSREQKYK
     TLKNILVCIM LFTFVIGKPS MEFEPYPQQP DTVWNQNQLF QYIVRSALFS PVSLRQTVTE
     ALTTFSRQFL RDFLQGLSDA EQVTKLYAKA SKIGDVLKVS EQMLFALRTI SDVRMEGLDS
     ESIIYDLAYT FLLKSLLPTI RRCLVFIKVL HELVKDSENE TLVINGHEVE EELEFEDTAE
     FVNKALKMIT EKESLVDLLT TQESIVSHPY LENIPYEYCG IIKLIDLSKY LNTYVTQSKE
     IKLREERSQH MKNADNRLDF KICLTCGVKV HLRADRHEMT KHLNKNCFKP FGAFLMPNSS
     EVCLHLTQPP SNIFISAPYL NSHGEVGRNA MRRGDLTTLN LKRYEHLNRL WINNEIPGYI
     SRVMGDEFRV TILSNGFLFA FNREPRPRRI PPTDEDDEDM EEGEDGFFTE GNDEMDVDDE
     TGQAANLFGV GAEGIAGGGV RDFFQFFENF RNTLQPQGNG DDDAPQNPPP ILQFLGPQFD
     GATIIRNTNP RNLDEDDSDD NDDSDEREIW
//
